SCHEMBL3970237

SCHEMBL3970237

O=C(O)[C@H](Cc1ccc(O)cc1)NCc1ccccc1[N+](=O)[O-]

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
KDM4A O75164 1/20 0.57
ITGA4 P13612 4/20 0.50
ITGB7 P26010 4/20 0.50
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 2/20 0.46
PDCD1 Q15116 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
MME P08473 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 2/20 0.44
ACE P12821 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3970236 1.00 ALDH1A1 (0.57) ALDH1A1KDM4AITGA4ITGB7KMT2A
SCHEMBL14921097 0.92 ALDH1A1 (0.66) ALDH1A1KDM4AITGA4ITGB7KMT2A
SCHEMBL20515138 0.87 ALDH1A1 (0.51) ALDH1A1KDM4AITGA4ITGB7KMT2A
SCHEMBL20515136 0.87 ALDH1A1 (0.51) ALDH1A1KDM4AITGA4ITGB7KMT2A
SCHEMBL7518908 0.87 ITGA4 (0.54) ALDH1A1KDM4AITGA4ITGB7PDCD1
SCHEMBL7518902 0.87 ITGA4 (0.54) ALDH1A1KDM4AITGA4ITGB7PDCD1
SCHEMBL6616257 0.83 ALDH1A1 (0.60) ALDH1A1KDM4AITGA4ITGB7
SCHEMBL6616256 0.83 ALDH1A1 (0.60) ALDH1A1KDM4AITGA4ITGB7
SCHEMBL756835 0.82 ALDH1A1 (0.54) ALDH1A1KDM4AKMT2AKDM4EPDCD1
SCHEMBL756836 0.82 ALDH1A1 (0.54) ALDH1A1KDM4AKMT2AKDM4EPDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658394-B2 Methods, cells and systems for incorporating non-canonical amino acids into proteins WATERSTONE PHARMACEUTICALS (CN) 2014-02-25 US claimed
US-20120237971-A1 METHODS, CELLS AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS WATERSTONE PHARMACEUTICALS (CN) 2012-09-20 US claimed
WO-2012092629-A2 METHODS, CELLS, AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS WATERSTONE PHARMACEUTICALS (CN) 2012-07-05 WO claimed
EP-4720264-A1 AMINOACYL-TRNA SYNTHETASE SETS United Kingdom Research and Innovation (GB) 2026-04-08 EP disclosed
US-20250346939-A1 Method of Making Proteins with Non-Standard Amino Acids PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-11-13 US disclosed
US-20250320452-A1 MICROORGANISMS AND USES THEREOF RES & INNOVATION UK (GB) 2025-10-16 US disclosed
US-20250279156-A1 METHODS FOR OPTIMISING PROTEIN PRODUCTION UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2025-09-04 US disclosed
US-12385035-B2 Synthetic genome UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2025-08-12 US disclosed
US-20250206782-A1 BIOLOGICAL POLYMERS RES & INNOVATION UK (GB) 2025-06-26 US disclosed
WO-2024246123-A1 AMINOACYL-tRNA SYNTHETASE SETS UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2024-12-05 WO disclosed
US-20240229013-A9 SYNTHETIC GENOME SCARAB GENOMICS, LLC 2024-07-11 US disclosed
US-9834775-B2 Recombinant cells and organisms having persistent nonstandard amino acid dependence and methods of making them PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-05 US disclosed
US-20160230176-A1 Recombinant Cells and Organisms Having Persistent Nonstandard Amino Acid Dependence and Methods of Making Them NATIONAL SCIENCE FOUNDATION 2016-08-11 US disclosed
WO-2015048364-A1 RECOMBINANT CELLS AND ORGANISMS HAVING PERSISTENT NONSTANDARD AMINO ACID DEPENDENCE AND METHODS OF MAKING THEM PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-04-02 WO disclosed
US-8658394-B2 Methods, cells and systems for incorporating non-canonical amino acids into proteins WATERSTONE PHARMACEUTICALS (CN) 2014-02-25 US disclosed
CN-102827827-A Orthogonal translation components for in vivo incorporation of unnatural amino acids SCRIPPS RESEARCH INST 2012-12-19 CN disclosed
US-20120237971-A1 METHODS, CELLS AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS WATERSTONE PHARMACEUTICALS (CN) 2012-09-20 US disclosed
WO-2012092629-A2 METHODS, CELLS, AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS WATERSTONE PHARMACEUTICALS (CN) 2012-07-05 WO disclosed
WO-2009049223-A2 METHODS AND COMPOSITIONS FOR THE SITE-SELECTIVE INCORPORATION OF FLUORINATED AMINO ACIDS INTO POLYPEPTIDES IRM LLC (BM) 2009-04-16 WO disclosed
CN-101048506-A Orthogonal translation Components for in vivo incorporation of unnatural amino acids SCRIPPS RESEARCH INST (US) 2007-10-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206782-A1 BIOLOGICAL POLYMERS NSUN3, AARS1, TARBP1 ALDH1A1 4335/4885KDM4A 3685/4885ITGA4 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.